The Value of Self-Care in Public Health: Insights and Implications for Europe

By Rene Pretorius

July 2, 2025

Summary
Self-care in public health is a critical pillar of public health in Europe. It enables individuals to manage minor ailments independently while easing pressure on healthcare systems. By using non-prescription medicines, devices, and supplements, self-care cuts costs, saves time, and boosts productivity. Evidence shows that the value of self-care in public health amounts to annual savings of €36 billion and averted productivity losses of €10 billion.

Key Insights
Reported study findings highlight self-care’s economic and social value. Europe avoids €36 billion yearly by managing 1.2 billion minor health issues through self-care. This includes €26 billion in medical expenses and €10 billion in productivity losses. Self-care also reduces GP workloads. It equals needing 120,000 extra doctors or 2.4 more hours daily for current practitioners. Consumer behavior is shifting toward prevention. 84% take preventive measures, and 67% spend over €21 monthly on health aids.

Background Context
Research shows self-care’s role in tackling healthcare challenges. The AESGP notes it empowers individuals with low-cost solutions for minor ailments. EU eHealth initiatives improve access to electronic records. The eHealth score reached 83% in 2024, supporting self-care goals.

Implications
For health economics, self-care offers a scalable, cost-effective solution. It helps strained systems as populations age and chronic diseases rise. Stronger policies could optimize resources, letting providers focus on complex cases. Public health efforts can align with preventive trends, reducing reliance on costly interventions. Barriers like uneven regulations and education gaps may limit uptake. Future steps include digital health tools to enhance self-care, matching EU digital goals.

Reference url

Recent Posts

Rapid Genetic Testing Mitigates Gentamicin-Induced Hearing Loss in Neonates

By João L. Carapinha

March 9, 2026

Rapid genetic testing is dramatically improving neonatal care by detecting the m.1555A>G mitochondrial variant in newborns at risk of profound hearing loss from gentamicin, allowing swift switches to alternative antibiotics without delaying treatment. Developed through the
EMA’s Clinical Trials Guidance for Enhancing Flexibility During Public Health Emergencies
The European Medicines Agency (EMA) has released draft clinical trials guidance for public consultation from 4 March to 30 April 2026. This guidance outlines regulatory flexibi...
Portugal Clinical Trials Regulation: A Comprehensive Framework for EU Compliance and Participant ...
Portugal Aligns with EU Standards Portugal clinical trials regulation is now firmly established through Lei n.º 9/2026, published on March 6, 2026, which implements the European Parliament and Council